By asianet
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an underwritten public offering to sell 6,500,000 shares of its common stock at a public offering price of $10.00 per share, or $65 million worth of shares of its common stock. In … Continued
By asianet
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of $150 million aggregate principal amount of its 5.00% convertible senior notes due 2027 (the “notes”). The notes are being offered and sold only to persons reasonably believed to be … Continued
By asianet
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed offering of $125 million aggregate principal amount of convertible senior notes due 2027 (the “notes”). The notes will be offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant … Continued
By asianet
V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency Interim analysis demonstrated leniolisib to be well tolerated and indicated the durability of the efficacy results seen in the Phase II/III randomized, controlled trial Pharming Group N.V. (“Pharming” or “the … Continued
By asianet
Hovione and GEA today announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years. It combines GEA´s engineering expertise with Hovione´s development and manufacturing experience and both parties commit to partner to accelerate the adoption of Continuous Tableting technology. The advantages of continuous over batch manufacturing … Continued
By asianet
Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems’ CELLSEARCH(R) System and the CELLSERCH(R) Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with Multiple Myeloma (MM) even at asymptomatic precursor stages /PRNewswire/ — Menarini Silicon Biosystems, a pioneer of liquid biopsy and single … Continued
By asianet
Ubie, Inc., a Tokyo-based healthcare startup, announced on December 8 that it has closed its Series C round at $45 million by raising $19 million in an extension round. The new funding will enable Ubie to accelerate its growth and strengthen its presence in the U.S., following strong interest and traction in that market. To … Continued
By asianet
On Radar takes off, the first meeting of the Think Tank of Fondazione Internazionale Menarini Setting real changes in motion through dialogue among experts in order to tackle the unresolved issues of juvenile distress. This was the topic addressed during the first meeting of the ‘On Radar’ Think Tank of Fondazione Internazionale Menarini held in … Continued
By asianet
Leniolisib was well tolerated and significant improvement over placebo was notable in the co-primary endpoints, reflecting a favorable impact on patients’ immune dysregulation and deficiency The peer-reviewed publication heightens international understanding of APDS, a rare and recently characterized immunodeficiency Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces today that the … Continued
By asianet
The bone-derived skeletal growth factor (SGF), jointly developed by a research facility under the direction of leading biochemist, academician and researcher Zhao Yufen and the Anhui-based research center of one of the world’s health industry leaders People’s GuoTai Group (PGTG), broke through the formula stability bottleneck after unremitting efforts over the last three years and … Continued